WO2000049038A9 - Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung - Google Patents
Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendungInfo
- Publication number
- WO2000049038A9 WO2000049038A9 PCT/DE2000/000525 DE0000525W WO0049038A9 WO 2000049038 A9 WO2000049038 A9 WO 2000049038A9 DE 0000525 W DE0000525 W DE 0000525W WO 0049038 A9 WO0049038 A9 WO 0049038A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vpr
- glu
- arg
- leu
- ile
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 85
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title claims abstract description 38
- 241000700605 Viruses Species 0.000 title claims abstract description 19
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 title claims description 31
- 102000004169 proteins and genes Human genes 0.000 title claims description 20
- 101710149136 Protein Vpr Proteins 0.000 claims abstract description 169
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 55
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 239000012634 fragment Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 102100040396 Transcobalamin-1 Human genes 0.000 claims abstract description 4
- 101710124861 Transcobalamin-1 Proteins 0.000 claims abstract description 4
- 238000004166 bioassay Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 24
- 208000031886 HIV Infections Diseases 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 230000002950 deficient Effects 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 6
- 108090000862 Ion Channels Proteins 0.000 claims description 6
- 102000004310 Ion Channels Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000010354 integration Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 238000012512 characterization method Methods 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 238000009589 serological test Methods 0.000 claims description 5
- 101710177291 Gag polyprotein Proteins 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 238000010171 animal model Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 claims description 3
- 101800001415 Bri23 peptide Proteins 0.000 claims description 3
- 102400000107 C-terminal peptide Human genes 0.000 claims description 3
- 101800000655 C-terminal peptide Proteins 0.000 claims description 3
- 102400000108 N-terminal peptide Human genes 0.000 claims description 3
- 101800000597 N-terminal peptide Proteins 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000025084 cell cycle arrest Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000003950 pathogenic mechanism Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 238000002953 preparative HPLC Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000012916 structural analysis Methods 0.000 claims description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000033616 DNA repair Effects 0.000 claims description 2
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 claims description 2
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 claims description 2
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 claims description 2
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 claims description 2
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims description 2
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 claims description 2
- 101001094146 Homo sapiens SUMO-activating enzyme subunit 2 Proteins 0.000 claims description 2
- 101000717428 Homo sapiens UV excision repair protein RAD23 homolog A Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 101710203526 Integrase Proteins 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 102100035250 SUMO-activating enzyme subunit 2 Human genes 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 102100020845 UV excision repair protein RAD23 homolog A Human genes 0.000 claims description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 229940043517 specific immunoglobulins Drugs 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 230000032258 transport Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 abstract description 15
- 238000004458 analytical method Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 2
- 102400000700 Tumor necrosis factor, membrane form Human genes 0.000 abstract 1
- 101800000716 Tumor necrosis factor, membrane form Proteins 0.000 abstract 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- -1 fluoromethyloxycarbonyl Chemical group 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 2
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108700026215 vpr Genes Proteins 0.000 description 2
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102100038780 Carbohydrate sulfotransferase 7 Human genes 0.000 description 1
- 101710158444 Carbohydrate sulfotransferase 7 Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- AGXPTZJCBJSVQH-UHFFFAOYSA-N FC(C(=O)O)(F)F.C(C)(C)[SiH](C(C)C)C(C)C.C(C)(S)S Chemical compound FC(C(=O)O)(F)F.C(C)(C)[SiH](C(C)C)C(C)C.C(C)(S)S AGXPTZJCBJSVQH-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 230000005375 negative regulation of lymphocyte activation Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000004104 two-dimensional total correlation spectroscopy Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 101150024249 vpr gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention relates to synthetic peptides of the regulatory virus protein R (Vpr) of the human immunodeficiency virus type 1 (HIV-1). in particular the chemical total synthesis of the 96 amino acid long Vpr protein (sVprl-96) and its sequences.
- Vpr regulatory virus protein
- sVprl-96 96 amino acid long Vpr protein
- synthetic Vpr peptides they are used in biological assays, in the analysis of the molecular structure and the physicochemical properties of Vpr and its domains, and for the generation of antibodies against Vpr peptide sequences.
- Vpr The only biochemical activity of Vpr characterized so far in vitro is that of a cation-selective ion channel (Piller et al. 1996. - bibliography at the end of the exemplary embodiments).
- This work was based on the assumption that the C-terminal alpha helix (positions 46 to 71 in Vpr), which has similarities to the bee venom component melittin, can form a membrane pore as a transmembrane anchor.
- recombinant Vpr expressed in Escherichia (E.) coli could be reconstituted in artificial planar lipid bilayers.
- an ion channel activity which could be regulated by the membrane potential was determined, the controllability of which depends on the basic C-terminal region which is to interact with the negatively charged cytoplasmic side of the cell membrane.
- Vpr A recombinant Vpr fusion protein forms oligomeric structures with molecular weights of> 100 kDa (Zhao et al., 1994b), an observation that has not been confirmed on viral Vpr so far.
- Vpr studies on the molecular structure of Vpr were carried out by two groups using secondary structure analyzes on short Vpr peptides: NMR studies on overlapping peptides in aqueous trifluoroethanol (TFE) and alpha-helical regions identified in sodium dodecyl sulfate (SDS) micelles in the Vpr Positions 50-82. (Yao et al, 1998). The potential for helix formation in the C-terminal as well as the N-terminal region of Vpr has previously been predicted by various authors (Mahalingam et al. 1995a-d: Yao et al. 1995: Wang et al. 1996b).
- Vpr peptide does not bind to p6 G ⁇ g , a widely accepted property of Vpr (Paxton et al, 1993; Lavallee et al. 1994; Kondo et al. 1995: Lu et al. 1995; Kondo and Göttlinger. 1996).
- this peptide does not form oligomers, and there are indications that this peptide is insoluble in a purely aqueous system.
- Roques et al, 1997) presented a model of the Vpr-NCp7 interaction, which is based on structural analyzes of partial sequences of these peptides.
- Vpr. Short, about 20 amino acid long peptides of the C-terminal region of Vpr. which contain the motif "HF / SRIG " , have a concentration of 0.7 to 3 micro-M cytotoxic effects against various yeast strains, such as Saccharomyces cerevisiae. Triggers Candida albicans and Schizosaccharomyces pombe (Macreadie et al. 1996, 1997). An increased concentration of divalent cations, especially magnesium and calcium, prevents the uptake of the Vpr peptides and thereby their toxic effects. Further studies showed that a C-terminal Vpr peptide (positions 71-82) membrane permeabilization.
- Recombinant Vpr of the isolate HIV-1 N _ 3 was expressed in insect cells after infection with recombinant baculoviruses (Levy et al, 1995). The purification of the product was carried out only by immunoaffinity chromatography on immobilized polyclonal antiserum which is directed against the N-terminal domain of Vpr. Cell culture supernatants were used for this, since recombinant Vpr is secreted non-specifically into the culture medium. Purification strategies for the production of large amounts of recombinant Vpr have not been described. In most cases, authors used Vpr-containing cell culture supernatants for biological tests. It could be shown that recombinant Vpr activates the virus rephcation in PBMC (peripheral blood mononuclear cells) and in various latently infected monocyte and T cell lines. The main disadvantages of this procedure are:
- Vpr Recombinant Vpr was mixed with detergents in the process of affinity purification, which made dialysis and renaturation necessary;
- Vpr The effect of recombinant Vpr in HIV-infected primary monocytes / macrophages has not been tested.
- Expression Purification and biochemical characterization of recombinant Vpr were first described in 1994 by Zhao and co-workers. For this purpose, the coding sequence of the Vpr protein of the isolate HIV-1 8 9 6 was expressed in E. coli as a fusion protein. For the purpose of purification and detection, a 25 amino acid sequence of the heterologous FLAG epitope was fused C-terminally in this method. Except for the oligomerization reported no biological activities of the recombinant product in this work. A major disadvantage of this method is the fact that Vpr is not expressed in its authentic sequence, but as a fusion protein.
- Vpr of the isolate HIV-1 HXB2 was expressed in E. coli as a GST-5 fusion protein (Piller et al, 1996). After affinity chromatography on glutathione agarose, Vpr was freed of the fusion portion by thrombin cleavage.
- a major disadvantage of this method is the fact that Vpr has a strong tendency to aggregate after cleavage and cannot be kept in aqueous solution. For example, Arunagiri and co-workers (1997) report that recombinant Vpr
- Patent application WO 95/26361 (Azad, A.A .. Macreadie, LG .. Arunagiri, C, 1995) describes biologically active peptide fragments of the Vpr protein of HIV;
- chimeric molecules are protected, consisting of Vpr from HIV-1 and Vpx from HIV-2, which can be specifically incorporated into HIV-1 / HIV-2 virus particles and disrupt the structural organization and functional integrity of virions there , However, they are excluded for use in gene therapy for HIV-1 / HIV-2 infections.
- WO 96/08970 Weiner, D.B .; Levy, D.N .; Refaeli, Y., 1996) describes methods for
- Vpr proteins 25 Inhibition of cell division and lymphocyte activation using Vpr proteins, fragments of Vpr or gene sequences of Vpr are described. The chemical synthesis of Vpr proteins plays no role in this.
- the object of the invention is to develop a synthesis route for Vpr peptides on a mg scale, to enable their purification and to make the end product available to the general public.
- the object was achieved according to the invention by providing the protein sVprl-96 and the peptides
- sVpr41 -55 Asn-Leu-Gly-Gln-His-Ile-Tyr-Glu-Thr-Tyr-Gly-Asp-Thr-Ala-T ⁇ .
- sVpr46-60 Asn-Leu-Gly-Gln-His-Ile-Tyr-Glu-Thr-Tyr-Gly-Asp-Thr-Ala-T ⁇ .
- the C-terminal Vpr peptides were synthesized on a serine resin using a Perkin-Elmer synthesizer. All N-terminal peptides were synthesized on a polystyrene-polyoxyethylene carrier resin. The peptides were built up using FMOC (fluoromethyloxycarbonyl) strategy using protective groups. After the synthesis had ended, the protective groups were cleaved off using a cleavage mixture consisting of 95% trifluoroacetic acid. the 3% triisopropylsilane and, depending on the peptide, 2 to 5% ethanedithiol was added. The resin was separated off, the reaction solution was concentrated and heptane was added.
- FMOC fluoromethyloxycarbonyl
- the sVpr peptides produced according to the invention after this purification procedure - in contrast to the recombinant or synthetic products described hitherto - are water-soluble and are not subject to protein aggregation even in high concentrations of up to mM solutions. It could be shown that the protein sVprl-96 assumes a folded structure, has biological activities comparable to viral Vpr and is immunologically reactive.
- Vpr protein corresponds to the amino acid sequence of the virus isolate HIV-K - 3 .
- Vpr peptides are understood to mean the peptides produced by solid phase synthesis, which contain the authentic amino acid sequence of the native Vpr protein as encoded by the vpr gene of the molecular isolate HIV-1 L -3.
- the peptides can be produced under economically acceptable conditions on a mg scale and enriched to a high degree of purity. They show immunogenic and biological properties which are identical to those of natural Vpr proteins. They can be used for diverse areas of basic research as well as applied research in the field of HIV virology.
- the peptides according to the invention are used in biological assays, in the structural analysis of Vpr and its domains, for the generation of antibodies against HIV peptide sequences, in antiviral reagents, for the construction of test systems for the screening of potential Vpr antagonists, in the establishment of cell culture and Animal models, for the investigation of the pathomechanisms of Vpr, for the in vitro assembly of novel vectors for use in gene transfer methods in gene therapy and for the development of serological test methods, in particular a Vpr antigen ELISA.
- the products produced according to the invention can be used for the elucidation of the molecular structure of Vpr by means of NMR and CD spectroscopic methods as well as for crystallization and subsequent RKSA.
- This information is essential for understanding the molecular mode of action of the Vpr protein in the HIV-1 replication cycle and the associated pathomechanisms of AIDS, as well as the molecular design of potential Vpr antagonists.
- these products can be used to display in vitro test systems which allow the intensive screening of potential anti-Vpr-active reagents.
- they can be used for the generation and testing of Vpr-specific antibodies and for serological test procedures.
- the invention is in peptide chemistry. basic virological research, structural analysis and medical diagnostics.
- the invention can be used for the production of poly- and monoclonal Vpr-specific antibodies or antisera, especially for the production of epitope-different Vpr-specific antibodies.
- Other areas of application are: serological test methods, as Vpr antigen (Ag) ELISA, as standard antigen for the calibration of Vpr-Ag ELISA techniques, detection for determining the concentration of viral Vpr in the blood of HIV-infected individuals, test systems for the determination of Vpr antagonists.
- the invention is also useful for determining reagents that a) prevent Vpr from interacting with cellular factors such as the glucocorticoid receptor, transcription factors and other DNA interacting enzymes and factors; b) prevent the transcription activating effect of Vpr; regulate, influence or prevent the activity of Vpr on the effects of steroid hormones; c) regulate, influence or prevent the transport of Vpr alone or in combination with other components of the HIV pre-integration complex; regulate, influence or prevent the incorporation of Vpr into virus particles during HIV assembly; d) regulate, influence or prevent the effect of Vpr on cell differentiation and cell growth, regulate, influence or prevent the Vpr-induced cell cycle arrest e) regulate, influence or prevent the cytotoxic effects of Vpr and f) regulate, influence or prevent the ion channel activity of Vpr
- Vpr antagonists It is also used for in vivo test systems for the determination of Vpr antagonists possible.
- the invention is also suitable for animal model studies. Another advantage is that concentrated peptide solutions can be provided. In this way, specific Vpr antagonists can be produced.
- Another area of application is the reduction of the flexibility of sVpr protein induced by the N-terminal domain of Vpr by means of structure-stabilizing factors. These factors are the UBA2 domain of the DNA repair protein HHR23A. which binds to Vpr, Fab fragments of Vpr-specific immunoglobulins or viral factors, in particular components of the HIV-1 gag polyprotein precursor Pr55Gag, which in the process of virus assembly come into contact with Vpr, the human glucocorticoid receptor or components thereof.
- an in vitro assembly of retroviral pre-integration complexes in vitro or in vivo applicable gene transfer methods, transfections, integration into chromosomal and episomal host DNA or other gene transfer methods in eukaryotic cells or gene transfers of in vitro produced and / or manipulated gene fragments in cells , Tissues or organisms for the purpose of gene therapy application.
- Vpr peptides were synthesized on a serine resin from Rapp Polymer Tübingen on an ABI 433A synthesizer (Perkin Elmer).
- N-terminal peptides were synthesized on a polystyrene-polyoxyethylene carrier resin (TentaGel R-RAM resin from Rapp Polymer).
- the peptides were built up using FMOC (fluoromethyloxycarbonyl) strategy using the following protective groups: Ot.Butyl ester for Glu and Asp, OtBu ether for serine. Tyrosine and threonine. Boc (tert-butoxycarbonyl-) for lysine and tryptophan.
- Trt (trityl - triphenylmethyl-) for histidine, glutamine and asparagine and Pbf (2.2.4.6.7-pentamethyl-dihydrobenzofuran-5-sulfonyl-) for arginine.
- the protective groups were cleaved off using a cleavage mixture consisting of 95% trifluoroacetic acid. the 3% triisopropylsilane and, depending on the peptide, 2 to 5% ethanedithiol was added. The resin was separated off, the reaction solution was concentrated and heptane was added. It was concentrated again and the remaining oil was digested with diethyl ether. The crude peptide was suctioned off and then lyophilized from 10% acetic acid.
- the peptide was constructed on a TentaGel S-AC resin (0.20 mmol / gram) on an ABI 433. At the end of the synthesis, the FMOC protecting group was split off, the resin was washed successively with dimethylformamide and methylene chloride and dried. The peptide was then cleaved from the resin in the manner described at the outset and then purified.
- Molar mass 1 1378 found 1 1381 H-Met-Glu-Gln-Ala-Pro-Glu-Asp-Gln-Gly-Pro-Gln-Arg-Glu-Pro-Tyr-Asn-Glu-T ⁇ -Thr-Leu- Glu-Leu-Leu- Glu-Glu-Leu-Lys-Ser-Glu-Ala-Val-Arg-His-Phe-Pro-Arg-Ile-T ⁇ -Leu-His-Asn- Leu-Gly-Gln-His-Ile-Tyr-Glu- Thr-Tyr-Gly-Asp-Thr-T ⁇ -Ala-Gly-Val-Glu-Ala-Ile-Ile-Arg-Ile- Leu-Gln-Gln-Leu-leu-Phe-Ile-His-Phe-Arg- Ile-Gly-Cys-Arg-His-Ser-Arg-Ile-Gly-Val-Thr-Arg
- Example 4 sVprl-47 Analogous to Examples 1 to 3. Molar mass: 5728 found. 5728.8
- Example 5 sVpr48-96 Analogous to Examples 1 to 3.
- Example 7 sVprl-20 (Asn 5 '10 14 ) Analogous to Examples 1 to 3.
- Example 8 sVpr21-40 Analogous to Examples 1 to 3. Wild-type sequence H-Glu-Leu-Leu-Glu-Glu-Leu-Lys-Ser-Glu-Ala-Val-Arg-His-Phe-Asn-Arg- Ile-T ⁇ -Leu-His-NH 2
- a C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration. mitochondrial dysfunction and apoptosis of human CD4 + lymphocytes. Apoptosis 2: 69-76.
- LXX leucine triplet repeat sequence
- the carboxy-terminal domain is essential for stability and not for virion inco ⁇ oration of HIV-1 Vpr into virus particles. Virol.
- Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers.
- Vpr function oligomerization by the ⁇ -terminal domain.
- Vpr amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino
- Associated protein Vpr of HIV-1NL4-3 negatively charged N-terminus (marker (1), positions 1-17); Helix alpha- 1 (marker (2). Positions 18-37); an unspecified region (marker (3), positions 38-51); Helix alpha-2 (marker (4), positions 51-76); basic C-terminus (marker (8), positions 77-96). Overlapping, further areas are shown: a region rich in leucine and isoleucine, which is also referred to as a leucine zipper-like or "LR domain" (marker (5), positions 60-80); a region containing the repeating motif " HF / SRIG" (marker (6). positions 71-82); the presumed transmembrane anchor of Vpr, which is necessary for the ion channel activity of Vpr (marker (7), positions 52-79).
- Figure 2 Immunological reactivity of polyclonal antibodies specifically for sVprl-96 in Western blot and immunoprecipitation
- sVprl-96 Rabbit serum immunized with sVprl-96. R-96th was tested in Western blot (A) and immunoprecipitation (B). A dilution series of 0.01 to 10 ng s Vpr 1-96 was separated in SDS-PAGE (12.5% acrylic aide gel) (A). A similar dilution series of sVprl-96 was mixed with human serum, and the peptide sVprl-96 was isolated from this mixture by means of serum R-96 by immunoprecipitation, and subsequently also separated in SDS-PAGE (B). After electrotransfer on PVDF membranes, sVprl-96 was detected using R-96 antibodies and subsequent binding of 1251 protein G.
- the autoradiogram of a 2-day exposure is shown in (A) and (B).
- the positions of standard molecular weight proteins are on the left, and the positions of non-specific reaction with the heavy (hc) and light chain (lc) of the immunoglobulins used for immunoprecipitation are shown on the right.
- FIG. 3 sVprl-96 activates virus rephcation and increases the number of living cells in cultures of human PBMC Cultures of PHA and IL-2 activated PBMCs were infected with the same infectious doses of the following virus stocks: HIV-1NL4-3 (ABC), NL4-3 (AD8) (D) and the vpu-deficient mutant NL (AD8) -UDEL1 (E) and the vpr-deficient mutant NL (AD8) deltaR (F).
- the cultures were cultured in the presence of 10 nM sVprl-96 or 10 nM of the control peptide Vpu32-81.
- the virus release is shown as a profile of the virus-associated RT activity in the cell culture supernatant (A, C, D, E, F).
- (B) shows the number of living cells in the experiment of (A).
- Figure 4 sVprl-96 activates the replication competence of vpr-deficient HIV-1 mutants in cultures of primary human monocytes / macrophages isolated from different donors. Parallel cultures of differentiated MDM isolates, obtained from three different donors, were purified with the same infectious doses Virus stocks of the macrophage-tropic virus NL4-3 (AD8) and its vpr-deficient mutant NL (AD8) deltaR infected. Virus production was monitored over a period of approximately two months and plotted as virus-associated RT activity against time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/913,927 US6984486B1 (en) | 1999-02-19 | 2000-02-19 | Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof |
JP2000599775A JP2002540768A (ja) | 1999-02-19 | 2000-02-19 | ヒト免疫不全ウイルス1型(HIV−1)ウイルス性調節タンパク質R(Vpr)の合成ペプチドおよびその適用 |
EP00918674A EP1155035A2 (de) | 1999-02-19 | 2000-02-19 | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19908766A DE19908766C2 (de) | 1999-02-19 | 1999-02-19 | Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien |
DE19908752.0 | 1999-02-19 | ||
DE19908766.0 | 1999-02-19 | ||
DE19908752A DE19908752A1 (de) | 1999-02-19 | 1999-02-19 | Synthetische Peptide des regulatorischen Virusproteins R (Vpr) des Humanen Immundefizienzvirus Typ 1 |
CA002356390A CA2356390A1 (en) | 1999-02-19 | 2001-08-17 | Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000049038A2 WO2000049038A2 (de) | 2000-08-24 |
WO2000049038A3 WO2000049038A3 (de) | 2001-03-01 |
WO2000049038A9 true WO2000049038A9 (de) | 2001-05-17 |
Family
ID=27808200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2000/000525 WO2000049038A2 (de) | 1999-02-19 | 2000-02-19 | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1155035A2 (de) |
JP (1) | JP2002540768A (de) |
CA (1) | CA2356390A1 (de) |
WO (1) | WO2000049038A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664040B2 (en) | 2000-05-23 | 2003-12-16 | The Regents Of The University Of California | Compositions and methods for delivery of a molecule into a cell |
IL149279A0 (en) * | 2002-04-22 | 2002-11-10 | Yissum Res Dev Co | Anti-nls substances and uses thereof in nuclear import inhibition |
FR2860236B1 (fr) * | 2003-09-25 | 2006-01-06 | Theraptosis | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
WO2005103654A2 (fr) * | 2004-04-09 | 2005-11-03 | Bioalliance Pharma | Methode d’identification de composes actifs sur la replication du virus hiv. |
JP2008001598A (ja) * | 2004-10-12 | 2008-01-10 | Institute Of Physical & Chemical Research | アポトーシス誘導物質を含む医薬組成物 |
JP4769009B2 (ja) * | 2005-04-05 | 2011-09-07 | オリエンタル酵母工業株式会社 | Vpr特異的モノクローナル抗体を産生するハイブリドーマを作製するためのVpr抗原、抗Vpr特異的モノクローナル抗体産生ハイブリドーマとそのハイブリドーマの産生する抗Vpr特異的モノクローナル抗体およびそれを利用したVprの免疫学的測定 |
CA2645342A1 (en) * | 2006-03-10 | 2007-09-20 | Peptcell Limited | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580739A (en) | 1986-01-22 | 1996-12-03 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2 |
WO1995016705A1 (en) | 1993-12-15 | 1995-06-22 | The Trustees Of The University Of Pennsylvania | Vpr receptor protein |
EP0753006A4 (de) * | 1994-03-25 | 1999-04-14 | Biomolecular Res Inst Ltd | Die vpr- und vpx-proteine des hiv |
US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
US5763190A (en) | 1994-09-21 | 1998-06-09 | The Trustees Of The University Of Pennsylvania | Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein |
US5639619A (en) | 1994-10-13 | 1997-06-17 | Regents Of The University Of California | Screening assay for anti-HIV drugs using the Vpr gene |
US6328976B1 (en) * | 1997-04-04 | 2001-12-11 | Immune Response Corporation | Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor |
-
2000
- 2000-02-19 WO PCT/DE2000/000525 patent/WO2000049038A2/de active Application Filing
- 2000-02-19 EP EP00918674A patent/EP1155035A2/de not_active Withdrawn
- 2000-02-19 JP JP2000599775A patent/JP2002540768A/ja active Pending
-
2001
- 2001-08-17 CA CA002356390A patent/CA2356390A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2356390A1 (en) | 2003-02-17 |
WO2000049038A3 (de) | 2001-03-01 |
WO2000049038A2 (de) | 2000-08-24 |
JP2002540768A (ja) | 2002-12-03 |
EP1155035A2 (de) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60215626T2 (de) | Antagonist für die multimerisierung von hiv-1 vif-protein | |
DE69326069T2 (de) | Zusammensetzungen die die hiv replikation inhibieren | |
DE69434335T2 (de) | Synthetische peptidinhibitoren der hiv-übertragung | |
DE3855947T2 (de) | Peptide mit den immunologischen Eigenschaften von HIV-2 | |
MILLER et al. | A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides | |
DE68928130T2 (de) | Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung | |
DE69311427T2 (de) | Synthetische Polypeptide als Inhibitoren von HIV-1 | |
DE3752170T2 (de) | Synthetisches Antigen zum Nachweis von mit AIDS in Zusammenhang stehenden Krankheiten | |
DD283935A5 (de) | Verfahren zur herstellung eines aids-virus-impfstoffes | |
DE69133242T2 (de) | Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus | |
DE69434961T2 (de) | Funktion und aktivität des viralen proteins r (vpr) | |
WO2000049038A9 (de) | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung | |
DE69132795T3 (de) | Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt | |
EP3613762A1 (de) | Potentes hiv-hemmendes lipopeptid, derivat davon, pharmazeutische zusammensetzung davon und verwendung davon | |
DE69233455T2 (de) | Modifizierte proteine und deren verwendung zur kontrolle von virusinfektionen | |
DE69125161T3 (de) | Synthetische peptide und mischungen davon zum nachweis der gegen hiv-gerichteten antikörper | |
DE3889625T2 (de) | Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung. | |
DE69420042T2 (de) | Vielfältig verzweigte peptidkonstruktion zur bekämpfung von hiv | |
DE69207200T2 (de) | IMMUNTEST ZUM GLEICHZEITIGEN NACHWEIS VON HIV-1, HIV-2, HTLV-I und HTLV-II ANTIKÖRPERN | |
EP1228203B1 (de) | Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung | |
EP0732339B1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
WO1991018454A1 (en) | Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection | |
DE19908752A1 (de) | Synthetische Peptide des regulatorischen Virusproteins R (Vpr) des Humanen Immundefizienzvirus Typ 1 | |
DE3889945T2 (de) | Methoden und Materialien für die HIV-Erkennung und Therapie. | |
DE69433057T2 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 21-23, CLAIMS, REPLACED BY NEW PAGES 21-23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 599775 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000918674 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000918674 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09913927 Country of ref document: US |